



Vifor Pharma AG (Switzerland): Tender Offer

09 March 2022

CSL Behring AG (Switzerland, non constituent) have launched a public tender offer to shareholders of Vifor Pharma AG (Switzerland, BZ12TW4, GEIS Mid Cap), with an offer price of USD 179.25.

The additional acceptance period is expected to run from 09 March 2022 until 22 March 2022, with settlement of the offer expected to occur shortly after - subject to regulatory approval.

Following publication of the results of the main offer period, Vifor Pharma AG shares (ISIN: CH0364749348, Sedol: BZ12TW4) will be replaced with the tendered share class (ISIN: CH1156060167, Sedol: BNT86X0) within FTSE Russell indexes from the open of 14 March 2022.

Subject to outstanding regulatory approval and the publication of the results of the additional acceptance period, FTSE Russell will continue to monitor the event and will issue a further notice in due course.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2022 FTSE Russell